Avalon Ventures XI, L.P. - Jun 10, 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: 10%+ Owner
Signature: Avalon Ventures XI, L.P. By: Avalon Ventures XI GP, LLC, its general partner, By: /s/ Tighe Reardon, Authorized Signatory
Stock symbol: JANX
Transactions as of: Jun 10, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/10/2021, 07:28 PM
Next filing: Jun 16, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	JANX	Common Stock						192K	Jun 10, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	JANX	Series Seed Convertible Preferred Stock							Jun 10, 2021	Common Stock	1.14M		Direct	F1, F2
holding	JANX	Series Seed 2 Convertible Preferred Stock							Jun 10, 2021	Common Stock	2.38M		Direct	F1, F2
holding	JANX	Series A Convertible Preferred Stock							Jun 10, 2021	Common Stock	674K		Direct	F1, F2
holding	JANX	Series A Convertible Preferred Stock							Jun 10, 2021	Common Stock	2.7M		See footnote	F2, F3
holding	JANX	Series B Convertible Preferred Stock							Jun 10, 2021	Common Stock	1.15M		See footnote	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kevin Kinsella, Richard Levandov, Braden Bohrmann and Jay Lichter, Ph.D. are managing members of Avalon XI GP. Mr. Kinsella, Mr. Levandov, Mr. Bohrmann and Dr. Lichter share voting and investment power with respect to the shares held by Avalon Ventures. Each of such individuals disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of each such individual's actual pecuniary interest therein, if any.
F2	Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
F3	The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter and Tighe Reardon share voting and investment power with respect to the shares held by ABV SPV. Each of such individuals disclaims beneficial ownership of all shares held by ABV SPV except to the extent of each such individual's actual pecuniary interest therein, if any.